Article Text

Download PDFPDF

Heartbeat: the COVID-19 pandemic and the future of cardiology
Free
  1. Catherine M Otto
  1. Division of Cardiology, University of Washington, Seattle, Washington, USA
  1. Correspondence to Professor Catherine M Otto, Division of Cardiology, University of Washington, Seattle, Washington, USA; cmotto{at}uw.edu

Statistics from Altmetric.com

The COVID-19 pandemic created challenges which exposed inefficiencies, inequities, lack of resiliency and outdated models for the delivery of cardiovascular care around the globe. At the same time, the response to this crisis has allowed rapid transformation of our systems of care, including widespread use of digital interfaces, streamlining of care pathways and improved integration of patient-centric clinical services. In the hope of ensuring that this positive transformation is carried forward the British Cardiovascular Society (BCS) has outlined these changes and identified additional areas that require improvement as summarised in a short article in this issue of Heart 1 with the full report available on the BCS website.2 As they conclude: ‘cardiology, like other specialties, needs to assimilate and act on the lessons learnt during the pandemic. This will require a restructuring of the way that we all work and deliver clinical services.’ The insights summarised in the BCS report and the changes implemented by the NHS in the UK can provide a useful frame of reference that other healthcare systems around the world might consider in their long-term approach to improving care of patients with cardiovascular disease (figure 1).

Figure 1

Potential interactions between primary and secondary care. AECG, ambulatory ECG; CP, chest pain; CTCA, CT coronary angiography; EHR, electronic health records; EOL, end of life; EP, electrophysiology; GP, general practitioner; GPwSI, general practitioner with specialist interest; GUCH, grown-up congenital heart disease; HF, heart failure; NT-pro BNP, N terminal pro B-type natriuretic peptide; OOH, out of hours; OPD, out patient department; QI, quality improvement; RAAC, rapid access arrhythmia clinic; RACP, rapid access chest pain clinic; RAHF, rapid access heart failure; TLOC, transient loss of consciousness; TTE, transthoracic echocardiogram.

The association of low-income levels with adverse outcomes in patients with heart failure (HF) and the effects of universal health coverage on reducing those differences has not been well documented. In this issue of Heart, Hung and colleagues3 used nationwide data in Taiwan on 633 098 patients hospitalised for HF spanning the years from 1996 (just after implementation of a nationwide health insurance programme) to 2013. Overall, low-income patients, compared with high-income patients, had higher in-hospital mortality rates (5.07% vs 2.51%), higher HF readmission rates, and lower utilisation of guideline-directed medical therapy. However, the disparities in outcomes between low-income versus high-income patients appeared to dissipate over time (figure 2).

Figure 2

Temporal trends of heart failure (HF) readmission (A) and all-cause mortality (B) by three income groups over time (1996–2013). A marked decrease in the incidence of HF readmission and all-cause mortality was observed over time for the low-income group (expressed as HR, reference: high-income group). A linear trend analysis was used for adjusted HR for low-income versus high-income HF group (as reference) across observation time (per year as ordinal category).

In an editorial, Zimerman and Rohde4 suggest three possible explanations for the worse outcomes in low-income patients with HF: (1) poverty may be a marker of poor prognosis related to factors such as geographic barriers to access to healthcare, education levels, racial/ethnic biases, unemployment and stress levels; (2) poverty might cause adverse outcomes indirectly due to issues such as lack of expensive medications, inadequate nutrition and exercise; and (3) poverty might lead directly to poor health outcomes. The reasons for the improvement over time in income inequities in Taiwan are more difficult to explain. As the authors conclude: ‘Healthcare professionals should understand how poverty is an indicator and a cause of poor healthcare and strive to explore alternatives to patients.’

Another interesting article in this issue by Almorad and colleagues5 prospectively evaluated the accuracy of serum D-dimer levels for exclusion of left atrial (LA) thrombus in 142 patients with atrial fibrillation (AF) undergoing transoesophageal echocardiography (TOE) prior to planned cardioversions. Overall, D-dimer levels were lower in the 91% of patients with no LA thrombus compared with the 9% with an LA thrombus (729±611 vs 2376±1081 ng/L; p<0.05). Specificity of a D-dimer level less than 10 times the patient age had a specificity of 66% and sensitivity of 100% for detection of LA thrombus, suggesting that about 60% of the study group could have safely undergone cardioversion without TOE (figure 3).

Figure 3

Evolution of D-dimer levels according to age category in the two groups with or without left atrial (LA) thrombus. Above 60 years, difference between the two groups becomes significant (p<0.05). Group 1, patients without LA thrombus on transoesophageal echocardiography (TOE); group 2, patients with LA thrombus on TOE; yrs, years.

In an editorial, Sinning6 cautions that despite the appeal of this approach, particularly in avoiding unnecessary exposure of healthcare providers to the risk of COVID-19 infection, ‘the patients described might not reflect the ‘real world’ patient presenting to the emergency department with additional cardiovascular diseases, like severe mitral regurgitation, known cancer diagnosis or inflammatory diseases.’ Validation of the accuracy of D-dimer levels for excluding LA thrombus is needed in other populations before widespread implementation of this approach.

Our series of review articles on cardiovascular genetics7 continues in this issue of Heart with a discussion of the role of genetic testing in diagnosis and management of patients with hypertrophic cardiomyopathy (HCM).8 Genetic testing can provide a specific diagnosis and differentiate HCM from conditions with similar phenotypes. Clinicians should understand when genetic testing or referral to a genetic expert is appropriate, recognising the complexities in interpreting the genetic findings, implementing family screening, and counselling patients about pathogenic variants, variants of uncertain significance and even management of those with ‘negative’ genetic testing but a positive family history (figure 4).

Figure 4

Schematic for employing genetic testing in the proband (index patient) and family. ACC, American College of Cardiology; AHA, American Heart Association; ESC, European Society of Cardiology; HCM, hypertrophic cardiomyopathy; LVWT, left ventricular wall thickness; VUS, variant of unknown significance.

The Education in Heart article,9 in this issue, summarises management of advanced heart failure in patients with adult congenital heart disease, including the indications for and outcome with heart transplantation.

References

Footnotes

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.